C. Ola Landgren, Chief of the Division of Myeloma at University of Miami and Leader of Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center, shared a post by HealthTree Foundation on X, adding:
“Thank you HealthTree Foundation for the interview at EHA2024 on bispecific monoclonal antibodies in myeloma. Lots of exciting new data. Great for patients!”
Quoting HealthTree Foundation‘s post:
“MYELOMA: C. Ola Landgren, MD discusses the efficacy of bispecific antibodies and the role of precision medicine in managing this complex disease.”
Source: C. Ola Landgren/X and HealthTree Foundation/X